Biotie Therapies - Major shareholder announcements

NOTIFICATION UNDER CHAPTER 2, SECTION 10 OF THE FINNISH SECURITIES MARKET ACT REGARDING CHANGE IN HOLDINGS

BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 5 April, 2007

Biotie Therapies Corp. (the "Company") has gained knowledge of the
following notification under Chapter 2, Section 9 of the Finnish
Securities Market Act regarding a change in holdings on 30 March
2007:

The aggregate holding of Pequot Healthcare Fund, L.P., Pequot
Healthcare Offshore Fund, Inc., Premium Series PCC Limited - Cell 32,
Pequot Diversified Master Fund, Ltd., Pequot Healthcare Institutional
Fund, L.P. and Pequot Healthcare Emerging Markets Fund, Ltd.
(jointly, the "Funds") have increased from 23.16 % to 25.76 % of the
share capital and voting rights of the Company, calculated on the
basis of the number of shares registered in the Finnish Trade
Register on 4 April 2007. No individual Fund has decreased its
holding below or above 5 % of the voting rights and share capital in
the Company.

Under Chapter 2, Section 9 of the Securities Market Act regarding a
change in holdings the Funds aggregated holding has exceeded 25 % of
the voting rights in and number of shares of the Company as follows:


+-------------------------------------------------------------------+
| Shareholder                | Number of shares | Proportion of     |
|                            |                  | share capital and |
|                            |                  | voting rights     |
|----------------------------+------------------+-------------------|
| Pequot Healthcare Fund,    | 8,330,596        | 9.28 %            |
| L.P.                       |                  |                   |
|----------------------------+------------------+-------------------|
| Pequot Healthcare Offshore | 6,397,683        | 7.12 %            |
| Fund, Inc.                 |                  |                   |
|----------------------------+------------------+-------------------|
| Premium Series PCC Limited |   998,490        | 1.11 %            |
| - Cell 32                  |                  |                   |
|----------------------------+------------------+-------------------|
| Pequot Diversified Master  | 1,201,800        | 1.34 %            |
| Fund, Ltd                  |                  |                   |
|----------------------------+------------------+-------------------|
| Pequot Healthcare          | 1,704,406        | 1.90 %            |
| Institutional Fund, L.P    |                  |                   |
|----------------------------+------------------+-------------------|
| Pequot Healthcare Emerging | 4.500.000        | 5.01 %            |
| Markets Master Fund, Ltd   |                  |                   |
+-------------------------------------------------------------------+



The share capital of Biotie Therapies Corp. constitutes 89,800,660
shares in the aggregate and the number of voting rights attached to
the shares amounts to 89,800,660.

Turku, on 5 April, 2007


Timo Veromaa
President and CEO

For further information, please contact:

Timo Veromaa, President and CEO, Biotie Therapies Corp.
tel. +358 2 274 8954, e-mail: timo.veromaa@biotie.com
www.biotie.com


DISTRIBUTION The Helsinki Stock Exchange
             Main Media